Incyte Corp ^Company

Incyte Corp and Novartis are working together with a Janus kinase (JAK1/JAK2) inhibitor first approved by the FDA in 2011, with indications in polycythemia vera, myelofibrosis, and acute graft-versus-host disease. Marketed as Jakafi in the U.S. by Incyte, and as Jakavi outside the U.S. by Novartis. Incyte and Novartis said April 2 they planned to launch a Phase III clinical trial (RUXCOVID) to assess the efficacy and safety of Jakafi/Jakavi plus standard-of-care (SoC), compared to SoC therapy alone, in patients with COVID-19 associated cytokine storm.

Incyte is also working with Shanghai Hengrui Pharmaceutical on the development of treatments based on camrelizumab and thymosin. It is a humanized monoclonal antibody targeting PD-1 (Camrelizumab); 5-Da polypeptide hormone secreted by the thymus gland (thymosin). Chinese clinical trials assessing the combination treatment have been registered by Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) (ChiCTR2000029806) and Southeast University (NCT04268537).